S&P 500:  2,801.83  -2.66 (-0.09%)
DOW:  25,058.12  -6.38 (-0.03%)
NASDAQ:  7,820.20  -5.10 (-0.07%)

NASDAQ:GILD - Gilead Sciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Get Started
$77.37 +0.32 (+0.42 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$77.37
Today's Range$76.3610 - $77.70
52-Week Range$64.27 - $89.54
Volume5.66 million shs
Average Volume5.79 million shs
Market Capitalization$100.19 billion
P/E Ratio9.04
Dividend Yield2.96%
Beta1.12
Gilead Sciences logoGilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen Sciences Ireland UC, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:GILD
CUSIP37555810
Webwww.gilead.com
Phone650-574-3000

Debt

Debt-to-Equity Ratio1.32
Current Ratio2.84
Quick Ratio2.75

Price-To-Earnings

Trailing P/E Ratio9.04
Forward P/E Ratio13.43
P/E Growth-6.69

Sales & Book Value

Annual Sales$26.11 billion
Price / Sales3.85
Cash Flow$9.6592 per share
Price / Cash8.01
Book Value$15.69 per share
Price / Book4.93

Profitability

EPS (Most Recent Fiscal Year)$8.56
Net Income$4.63 billion
Net Margins14.03%
Return on Equity45.49%
Return on Assets15.63%

Miscellaneous

Employees10,000
Outstanding Shares1,300,260,000
Market Cap$100,185.10

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Tuesday, May 1st. Shareholders of record on Friday, June 15th will be given a dividend of $0.57 per share on Thursday, June 28th. This represents a $2.28 annualized dividend and a yield of 2.95%. The ex-dividend date of this dividend is Thursday, June 14th. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) issued its earnings results on Tuesday, May, 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.67 by $0.19. The biopharmaceutical company earned $5.09 billion during the quarter, compared to analysts' expectations of $5.40 billion. Gilead Sciences had a return on equity of 45.49% and a net margin of 14.03%. The business's revenue for the quarter was down 21.8% compared to the same quarter last year. During the same period last year, the company earned $2.23 EPS. View Gilead Sciences' Earnings History.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Gilead Sciences.

What price target have analysts set for GILD?

25 Wall Street analysts have issued 12-month price targets for Gilead Sciences' shares. Their forecasts range from $72.00 to $105.00. On average, they anticipate Gilead Sciences' stock price to reach $88.2271 in the next year. This suggests a possible upside of 14.0% from the stock's current price. View Analyst Ratings for Gilead Sciences.

What is the consensus analysts' recommendation for Gilead Sciences?

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 9 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:
  • 1. According to Zacks Investment Research, "Gilead is now banking on its HIV franchise and newer avenues like the CAR-T therapy to drive growth. The HIV franchise maintains momentum driven by the rapid adoption of Descovy-based regimens. The FDA approval of Biktarvy has further widened the portfolio. Biktarvy has also been approved in Europe which should boost sales further. The initial uptake of Yescarta is encouraging in the United States and the CHMP gave a positive opinion on the same. Meanwhile, Gilead is intending to foray into the NASH market with selonsertib and filgotinib. Both the candidates are being evaluated in late stage studies and a tentative approval will diversify Gilead’s portfolio. Shares have outperformed the industry in the year so far. Estimates for Q2 are up by two cents in the last thirty days ahead of the results (scheduled for July 25). However, Gilead’s HCV franchise is under pressure due to competitive and pricing pressure." (7/18/2018)
  • 2. Needham & Company LLC analysts commented, "Gilead reported $5.09B 1Q18 total revenue, below our $5.52B and consensus $5.3B ests. Product sales were $5.00B, below our $5.41B est. Gilead continues to lose share to Abbvie in HCV. Trend is worrisome, although mgmt still guiding for market share stabilization mid-2018. HIV sales in 1Q18 also disappointed, reportedly driven by bigger than expected seasonal inventory draw-down and generic TDF. Growth in HIV (i.e. Biktarvy success) is critical. NASH program has not yet distinguished itself, awaiting data from selonsertib Phase 3 trials (1H19) and 48wk combination Phase 2 trials (2020). Yescarta and cell therapy programs are in early stages." (5/2/2018)
  • 3. Leerink Swann analysts commented, "RARE’s 4Q report this afternoon was relatively in line with expectations. Incremental clinical updates for burosumab in young children and in adults with osteomalacia (bone softening) in the report further support the drug’s utility in both populations. The year ahead is shaping up to be catalyst-rich for RARE, with data from two gene therapy programs, the Phase 3 of trihep in Glut1 DS, and a decision on trihep registration plans in FAOD expected over the coming months. Although we continue to expect a slow rollout of burosumab (PDUFA date 4/17/18) and Mepsevii, we see opportunity for further upside in shares over the course of 2018. Maintain OW." (2/22/2018)
  • 4. BMO Capital Markets analysts commented, "Early biopotency signals from a single patient dosed with ABO-101 (for Sanfilippo B), demonstrate targeted reduction on toxic sugars." (2/7/2018)

Are investors shorting Gilead Sciences?

Gilead Sciences saw a decrease in short interest during the month of June. As of June 29th, there was short interest totalling 13,703,362 shares, a decrease of 16.0% from the June 15th total of 16,306,232 shares. Based on an average daily trading volume, of 6,622,004 shares, the short-interest ratio is currently 2.1 days. Currently, 1.1% of the shares of the company are sold short. View Gilead Sciences' Current Options Chain.

Who are some of Gilead Sciences' key competitors?

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:
  • Dr. John F. Milligan, CEO, Pres & Director (Age 57)
  • Ms. Robin L. Washington, CFO & Exec. VP (Age 55)
  • Mr. Kevin B. Young, Advisory (Age 60)
  • Dr. John G. McHutchison, Exec. VP of Research, Clinical R&D and Chief Scientific Officer
  • Mr. Brett A. Pletcher, Exec. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.

Has Gilead Sciences been receiving favorable news coverage?

Media coverage about GILD stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Gilead Sciences earned a news impact score of 0.04 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 47.00 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Swedbank (0.15%), Confluence Investment Management LLC (0.09%), Retirement Systems of Alabama (0.08%), NN Investment Partners Holdings N.V. (0.07%), Gateway Investment Advisers LLC (0.06%) and Fisher Asset Management LLC (0.04%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Which institutional investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including Sit Investment Associates Inc., ZWJ Investment Counsel Inc., Howard Capital Management Inc., JLB & Associates Inc., Hartford Investment Management Co., Nippon Life Global Investors Americas Inc., Nisa Investment Advisors LLC and Municipal Employees Retirement System of Michigan. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

Which institutional investors are buying Gilead Sciences stock?

GILD stock was acquired by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, Cornerstone Wealth Management LLC, Assenagon Asset Management S.A., Addenda Capital Inc., Columbus Macro LLC, State of Alaska Department of Revenue, Fisher Asset Management LLC and Manning & Napier Group LLC. View Insider Buying and Selling for Gilead Sciences.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $77.37.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $100.19 billion and generates $26.11 billion in revenue each year. The biopharmaceutical company earns $4.63 billion in net income (profit) each year or $8.56 on an earnings per share basis. Gilead Sciences employs 10,000 workers across the globe.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]


MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  1,777 (Vote Outperform)
Underperform Votes:  706 (Vote Underperform)
Total Votes:  2,483
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Featured Article: Understanding Price to Earnings Ratio (PE)
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.